Lemelson Capital Makes Short Case Against Ligand Pharma (LGND)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/19/2024
- Wall St set for flat open as Middle East jitters ease, Netflix slumps
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Stocks off two-month low as fear of Middle East escalation eases
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Netflix (NFLX) Tops Q1 EPS by 77c, Offers Guidance
- Netflix, Tesla, Amex, P&G fall premarket; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
UPDATE: Short-Seller Article on Ligand (LGND) is Silly, Underlying Strength Remains - Roth Capital
June 17, 2014 8:44 AM EDT(Updated - June 17, 2014 8:54 AM EDT)
Roth Capital keeps Ligand Pharma (Nasdaq; LGND) at Buy with a $92 price target following a recent short-seller article.
Analyst Joseph Pantginis commented, A web-based platform for investing articles published a strongly bearish article on LGND on Monday afternoon. LGND's stock subsequently lost most of the gain it had experienced earlier in the day following positive Phase I glucagon receptor antagonist data. We believe many of... More
LGD-6972 Could Drive Partnership; Roth Keeps Ligand Pharma (LGND) at 'Buy'
June 16, 2014 10:28 AM EDTRoth Capital affirms its Buy rating and $92 target price on Ligand Pharmaceuticals (Nasdaq: LGND) following data from the Phase I study of glucagon receptor antagonist LGD-6972.
Analyst Joseph Pantginis commented, LGND believes these data suggest that the molecule is potentially a best-inclass glucagon receptor antagonist. We are... More
Ligand Pharma (LGND) Issues Positive Update on LGD-6972 Phase 1 in T2D
June 16, 2014 8:03 AM EDTLigand Pharmaceuticals (Nasdaq: LGND) announced data from a Phase 1 clinical trial with LGD-6972 that demonstrate favorable safety, tolerability and pharmacokinetics in normal healthy volunteers and in subjects with type 2 diabetes mellitus, and also demonstrate a robust response on fasting plasma glucose after a single dose. LGD-6972 is Ligands novel glucagon receptor antagonist and these first-in-human data were presented at the American Diabetes Associations 74th... More
